NBIX earnings call for the period ending June 30, 2020.
News & Analysis: Neurocrine Biosciences
Rapid sales growth for its tardive dyskinesia drug fueled investor optimism.
Strong second-quarter results announced after the close Monday boosted market optimism about this small biotech.
The company just licensed four drug programs for a cool $165 million up-front payment -- with the potential to receive $1.7 billion in future milestone payments.
Shares fall hard after the company reports disappointing data from an important clinical trial.
The company reported second-quarter 2018 results.
Blowout quarterly results caused traders to cheer.
The biotech struck regulatory gold with its tardive dyskinesia drug, Ingrezza.